BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) EVP Aby J. Mathew sold 404 shares of the company's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $27.02, for a total transaction of $10,916.08. Following the transaction, the executive vice president now directly owns 262,715 shares in the company, valued at $7,098,559.30. The trade was a 0.15 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.
BioLife Solutions Stock Performance
Shares of NASDAQ:BLFS opened at $27.69 on Thursday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. BioLife Solutions, Inc. has a one year low of $14.50 and a one year high of $28.88. The business's 50-day simple moving average is $25.91 and its 200 day simple moving average is $24.27. The company has a market cap of $1.28 billion, a P/E ratio of -26.12 and a beta of 1.92.
Analysts Set New Price Targets
A number of research analysts have weighed in on BLFS shares. Benchmark reissued a "buy" rating and set a $30.00 price target on shares of BioLife Solutions in a research note on Thursday, December 19th. Craig Hallum raised their price target on BioLife Solutions from $30.00 to $32.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. Northland Securities upped their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an "outperform" rating in a research note on Wednesday. HC Wainwright cut their price target on shares of BioLife Solutions from $29.00 to $27.00 and set a "buy" rating on the stock in a research note on Monday, November 18th. Finally, KeyCorp lifted their target price on BioLife Solutions from $30.00 to $33.00 and gave the company an "overweight" rating in a report on Friday, December 13th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, BioLife Solutions currently has an average rating of "Moderate Buy" and an average price target of $29.43.
Collect $7k per month from Tesla’s SECRET dividend
From Investors Alley | Ad
Tesla doesn't pay a traditional dividend....
But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla…
Which could put up to $7,013 in your pocket every month…
Click here to discover the new #1 way to invest in Tesla
View Our Latest Stock Analysis on BLFS
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in BLFS. Fred Alger Management LLC increased its stake in BioLife Solutions by 6.0% during the 2nd quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider's stock worth $33,841,000 after buying an additional 88,840 shares during the period. State Street Corp grew its stake in shares of BioLife Solutions by 7.3% during the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider's stock valued at $35,364,000 after acquiring an additional 95,788 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of BioLife Solutions by 2.2% during the third quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider's stock valued at $21,107,000 after acquiring an additional 18,473 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of BioLife Solutions by 9.1% during the second quarter. Dimensional Fund Advisors LP now owns 794,971 shares of the medical equipment provider's stock worth $17,034,000 after acquiring an additional 66,422 shares during the last quarter. Finally, Rockefeller Capital Management L.P. lifted its stake in shares of BioLife Solutions by 81.3% in the third quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider's stock worth $14,661,000 after acquiring an additional 262,504 shares in the last quarter. 93.24% of the stock is currently owned by hedge funds and other institutional investors.
BioLife Solutions Company Profile
(
Get Free Report)
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
